Incident suicidal ideations in patients with T2DM
within 6−month follow−up time window
(comparison between propensity−score matched groups)

Population	Semaglutide group	Non−GLP1R agonist anti−diabetic medications group		HR (95% CI)
Overall (n = 27,276/group)	0.13% (36)	0.36% (98)		0.36 (0.25−0.53)
Women (n = 13,322/group)	0.12% (16)	0.37% (49)		0.32 (0.18−0.57)
Men (n = 13,717/group)	0.15% (20)	0.30% (41)		0.48 (0.28−0.81)
age <= 45 years (n = 4,529/group)	0.24% (11)	0.68% (31)		0.35 (0.18−0.69)
age 46−64 years (n = 14,648/group)	0.12% (17)	0.32% (47)		0.36 (0.20−0.62)
age > 65 years (n = 8,483/group)	0.12% (10)	0.24% (20)		0.34 (0.15−0.81)
Black (n = 4,232/group)	0.24% (10)	0.38% (16)		0.31 (0.11−0.84)
White (n = 17,586/group)	0.14% (24)	0.50% (87)		0.27 (0.17−0.42)

0.10 0.20 0.40 0.80   2.0   4.0 8.00

Hazard Ratio (HR)